Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 16/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.74 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.74 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.74 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.74 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.74 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | HTR2A | P28223 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diprafenone SCHEMBL8862790 | 0.99 | MEN1 (0.82) | MEN1KMT2AABCB1LMNACYP1A2 | |
| SCHEMBL1331632 | 0.90 | MEN1 (0.98) | MEN1KMT2AABCB1LMNACYP1A2 | |
| Propafenone SCHEMBL16730120 | 0.85 | ABCB1 (1.00) | MEN1KMT2AABCB1LMNACYP1A2 | |
| Propafenone SCHEMBL41413 | 0.85 | ABCB1 (1.00) | MEN1KMT2AABCB1LMNACYP1A2 | |
| Propafenone SCHEMBL30416841 | 0.85 | ABCB1 (1.00) | MEN1KMT2AABCB1LMNACYP1A2 | |
| Propafenone SCHEMBL27865 | 0.85 | ABCB1 (1.00) | MEN1KMT2AABCB1LMNACYP1A2 | |
| SCHEMBL15750367 | 0.84 | ABCB1 (0.77) | MEN1KMT2AABCB1LMNACYP1A2 | |
| Propafenone SCHEMBL41412 | 0.84 | MEN1 (1.00) | MEN1KMT2AABCB1LMNACYP1A2 | |
| Propafenone SCHEMBL5529275 | 0.84 | MEN1 (1.00) | MEN1KMT2AABCB1LMNACYP1A2 | |
| Propafenone SCHEMBL29384899 | 0.84 | MEN1 (1.00) | MEN1KMT2AABCB1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119570376-A | High-initial-adhesion adhesive-residue-free paper pressure-sensitive adhesive and manufacturing method thereof | 浙江金科胶材股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-106581680-A | Pharmaceutical composition for lowering food influences on drug absorption | 山东亨利医药科技有限责任公司 | 2017-04-26 | — | — | CN | claimed |
| US-9585884-B2 | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | claimed |
| US-20170002015-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2017-01-05 | — | — | US | claimed |
| US-9498481-B2 | Cyclopropyl modulators of P2Y12 receptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-11-22 | — | — | US | claimed |
| US-20160193212-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2016-07-07 | — | — | US | claimed |
| US-9255104-B2 | Cyclopropyl modulators of P2Y12 receptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20140286943-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2014-09-25 | — | — | US | claimed |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| WO-2005113012-A2 | BETA ADRENERGIC DRUG CONJUGATED TO BONE TARGETING MOIETY FOR MODULATING BONE MASS | BAYLOR COLLEGE OF MEDICINE (US) | 2005-12-01 | — | — | WO | claimed |
| WO-2005099699-A1 | COMBINATION OF (S)-AMLODIPINE AND A BETA-BLOCKER, AND METHODS FOR REDUCING HYPERTENSION | SEPRACOR INC. (US) | 2005-10-27 | — | — | WO | claimed |
| US-20050215537-A1 | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | PHARMACIA CORPORATION | 2005-09-29 | — | — | US | claimed |
| US-20040235809-A1 | Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure | PHARMACIA CORPORATION | 2004-11-25 | — | — | US | claimed |
| WO-2002009760-A9 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND BETA-ADRENERGIC ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORP (US) | 2003-09-04 | — | — | WO | claimed |
| EP-1303306-A2 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND BETA-ADRENERGIC ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | Pharmacia Corporation (US) | 2003-04-23 | — | — | EP | claimed |
| US-20020123485-A1 | Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | PHARMACIA CORPORATION | 2002-09-05 | — | — | US | claimed |
| WO-2002009760-A2 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND BETA-ADRENERGIC ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002015-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | MEN1 4315/4885KMT2A 4533/4885ABCB1 516/4885 |
| US-20160193212-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | MEN1 4315/4885KMT2A 4533/4885ABCB1 516/4885 |
| US-20040235809-A1 | Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure | ADRB1, ADRB2, NR3C2 | MEN1 3463/4885KMT2A 3611/4885ABCB1 277/4885 |
| US-20020123485-A1 | Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | ADRB2, ADRB1, NR3C2 | MEN1 2795/4885KMT2A 3879/4885ABCB1 317/4885 |
| US-20050215537-A1 | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | ADRB1, ADRB2, ADRB3 | MEN1 2566/4885KMT2A 3624/4885ABCB1 199/4885 |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G1B, PLA2G4A, PLA2G4B | MEN1 3297/4885KMT2A 1547/4885ABCB1 1820/4885 |
| US-20140286943-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | MEN1 4315/4885KMT2A 4533/4885ABCB1 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.